pentoxifylline
CLINICAL USE
Peripheral vascular disease Venous leg ulcers (unlicensed indication)
DOSE IN NORMAL RENAL FUNCTION
400 mg 2 to 3 times daily
PHARMACOKINETICS
Molecular weight                           :278.3 %Protein binding                           :0 %Excreted unchanged in urine     : 0 (95% as active metabolites) Volume of distribution (L/kg)       :2.4–4.2half-life – normal/ESRD (hrs)      :0.4–1/Unchanged (see ‘Other Information’) DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
30–50 Dose as in normal renal function10–30 Reduce dose by 30–50% depending on individual tolerance (400 mg once or twice daily) <10           : Reduce dose by 30–50% depending on individual tolerance (400 mg once or twice daily) DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. 400 mg daily, slowly increasing if necessary HD                     :Not dialysed. 400 mg daily, slowly increasing if necessaryHDF/high flux   :Unknown dialysability. 400 mg daily, slowly increasing if necessaryCAV/VVHD      :Not dialysed. Dose as in GFR=10–30 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAnalgesics: possibly increased risk of bleeding when administered in combination with NSAIDs; increased risk of bleeding with ketorolac – avoid concomitant use ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
May enhance hypoglycaemia Avoid in porphyria Active metabolites are renally excreted and have an extended half-life in renal impairment
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home